Outcomes of Patients with Advanced Urothelial Carcinoma after Anti-programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study.
Eur Urol Open Sci
; 47: 48-57, 2023 Jan.
Article
en En
| MEDLINE
| ID: mdl-36601039
ABSTRACT
Background:
Clinical outcomes of anti-programmed death(ligand) 1 (anti-PD-[L]1) therapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa+) remain unclear; recent studies have reported either comparable or poorer outcomes versus patients without FGFR alterations (FGFRa-).Objective:
To analyze the outcomes of patients with mUC and any FGFRa (mutations or fusions) who received anti-PD-(L)1 therapy. Design setting andparticipants:
In this noninterventional, retrospective, multicenter study, clinical practice data were collected from FGFRa+/- patients who received prior immunotherapy between May 2018 and July 2019. Outcome measurements and statisticalanalysis:
Investigatordetermined overall response rate (ORR), disease control rate (DCR), and overall survival (OS) were assessed in multivariate and unadjusted analyses. Results andlimitations:
Ninety-four patients (66% men; median age, 63 yr) with mUC and known FGFR status were included; 38 (40%) were FGFRa+ and 56 (60%) were FGFRa-. In FGFRa+ versus FGFRa- patients who received any line of anti-PD-(L)1 therapy (nâ¯=â¯92), ORR, DCR, and OS were 16% versus 26%, 29% versus 52% (relative risk 1.14 [95% confidence interval {CI}, 0.92-1.40]; pâ¯=â¯0.3), and 8.57 versus 13.2 mo (hazard ratio [HR] 1.33 [95% CI, 0.77-2.30]; pâ¯=â¯0.3), respectively. A multivariate analysis provided some evidence supporting shorter OS in FGFRa+ versus FGFRa- (any line of anti-PD-L[1] therapy; HR 1.81 [95% CI, 0.99-3.31]; pâ¯=â¯0.054). Limitations include this study's retrospective nature and a potential selection bias from small sample size.Conclusions:
Some evidence of lower response rates and shortened OS following anti-PD-(L)1 therapy was observed in FGFRa+ patients. The phase 3 THOR study (NCT03390504) will prospectively compare FGFRa+ patients with advanced mUC treated with erdafitinib versus pembrolizumab. Patientsummary:
Patients with metastatic urothelial carcinoma and prespecified fibroblast growth factor receptor alterations (FGFRa) potentially have worse clinical outcomes when treated with anti-PD-(L)1 therapy than those without FGFRa.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Observational_studies
Idioma:
En
Revista:
Eur Urol Open Sci
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos